Adjustment of DOses of NIcotine in Smoking Cessation (ADONIS)
キーワード
概要
説明
Smokers currently smoking at least 10 cigarettes per day with smoking related diseases are included. They are randomized either to receive standard nicotine replacement therapy (24 h nicotine patch 21, 14, 7 mg/day for one month each, respectively), control arm, or nicotine dose adjustment according their saliva cotinine: dose adaptation arm. In the control arm, at the discretion of the investigators, buccal forms of nicotine replacement therapies are allowed. In both arms, saliva cotinine determinations are performed every 2 weeks for 2 months. In the control arm saliva cotinine results are not communicated to the investigators. In the dose adaptation arm investigators receive saliva cotinine results and should adapt the nicotine doses (mg of nicotine/day) according to baseline (when smoking) saliva cotinine to obtain 100 % substitution. Smokers are assessed at weekly visits after the predetermined quit day for 3 months. Follow up at 6 months. Main outcome measure: sustained abstinence (self reported no smoking and expired air carbon monoxide concentration equal or less than 8 ppm during the last (3rd) month of the treatment phase.
日付
| 最終確認済み: | 02/28/2007 |
| 最初に提出された: | 10/05/2005 |
| 提出された推定登録数: | 10/05/2005 |
| 最初の投稿: | 10/09/2005 |
| 最終更新が送信されました: | 03/27/2008 |
| 最終更新日: | 03/31/2008 |
| 実際の研究開始日: | 09/30/2005 |
| 一次完了予定日: | 10/31/2007 |
| 研究完了予定日: | 10/31/2007 |
状態または病気
介入/治療
Procedure: 1
Drug: 2
段階
アームグループ
| 腕 | 介入/治療 |
|---|---|
| Experimental: 1 adaptation of the nicotine patch with salivary cotinine | Procedure: 1 Dose adjustment of nicotine replacement therapies |
| Other: 2 normal following with a nicotine patch | Drug: 2 normal following with a nicotine patch |
適格基準
| 研究の対象となる年齢 | 18 Years に 18 Years |
| 研究に適格な性別 | All |
| 健康なボランティアを受け入れる | はい |
| 基準 | Inclusion Criteria: - Age ≥18 years Smoking ≥ 10 cigarettes per day Patients with disease conditions known to be related to smoking: e.g.coronary heart diseases, COPD, lower extremity arterial disease, etc Exclusion Criteria: - Smokers whose follow-up during the duration of the study, in a predictable way, cannot be assured. - smokers having been treated by bupropion ( Zyban) during two months preceding the inclusion - persons under TSN, neuroleptic, substitute treatments in OPINOIDES, under anticoagulants-non-equilibrating, - encircled woman - breast-feeding woman - Contraindication usual of the TSN |
結果
主な結果の測定
1. sustained smoking abstinence [during the study]
二次的な結果の測定
1. point prevalence abstinence,craving for tobacco,symptoms of nicotine withdrawal,weight,saliva cotinine concentration,genetic polymorphisms as predictors of therapeutic response and in interaction with nicotine replacement therapies [during the study]
